Thera-SAbDab

NATALIZUMAB

>   Structural Summary
TherapeuticNatalizumab
TargetITGA4
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv Structure4irz [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Natalizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 101 102 103 104 105 106 107 108 109 110 111 112 113
natalizumab Q V Q L V Q S G A E V K K P G A S V K V S C K A S G F N I K D T Y I H W V R Q A P G Q R L E W M G R I D P A N G Y T K Y D P K F Q G R V T I T A D T S A S T A Y M E L S S L R S E D T A V Y Y C A R E G Y Y G N Y G V Y A M D Y W G Q G T L V T V S S
4irz Q V Q L V Q S G A E V K K P G A S V K V S C K A S G F N I K D T Y I H W V R Q A P G Q R L E W M G R I D P A N G Y T K Y D P K F Q G R V T I T A D T S A S T A Y M E L S S L R S E D E A V Y Y C A R E G Y Y G N Y G V Y A M D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 96 97 98 99 100 101 102 103 104 105 106 107
natalizumab D I Q M T Q S P S S L S A S V G D R V T I T C K T S Q D I N K Y M A W Y Q Q T P G K A P R L L I H Y T S A L Q P G I P S R F S G S G S G R D Y T F T I S S L Q P E D I A T Y Y C L Q Y D N L W T F G Q G T K V E I K
4irz D I Q M T Q S P S S L S A S V G D R V T I T C K T S Q D I N K Y M A W Y Q Q T P G K A P R L L I H Y T S A L Q P G I P S R F S G S G S G R D Y T F T I S S L Q P E D I A T Y Y C L Q Y D N L W T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed1998
INN Year Recommended1999
Companies InvolvedBiogen, Biogen Idec, Elan Corporation, Perrigo
Conditions ApprovedCrohn's disease, Multiple sclerosis
Conditions ActiveEpilepsy, Graft-versus-host disease, Stroke
Conditions DiscontinuedMultiple myeloma, Rheumatoid arthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]